C4 Therapeutics, Inc.
CCCC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001662579
No open-market purchases or sales by C4 Therapeutics, Inc. insiders were filed in the last 90 days; 147 institutions reported holding it in 13F filings for Q2 2026, worth $547.6M in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in C4 Therapeutics, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 118
- +5 vs. Q2 2024
- Shares held
- 64.2M
- +7.97M (+14.2%) vs. Q2 2024
- Total value
- $365.9M
- +$106.2M (+40.9%) vs. Q2 2024
- New holders
- 31
- 37 more added
- Sold out
- 26
- 30 more reduced
2 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CCCC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 147 | $547.6M |
| Q1 2026 | 123 | $221.3M |
| Q4 2025 | 101 | $152.5M |
| Q3 2025 | 97 | $116.6M |
| Q2 2025 | 102 | $78.2M |
| Q1 2025 | 115 | $102.6M |
| Q4 2024 | 113 | $231.8M |
| Q3 2024 | 118 | $365.9M |
| Q2 2024 | 115 | $281.3M |
| Q1 2024 | 106 | $475.6M |
| Q4 2023 | 92 | $265.6M |
| Q3 2023 | 84 | $64.5M |
| Q2 2023 | 100 | $94.1M |
| Q1 2023 | 121 | $117.5M |
| Q4 2022 | 117 | $231.4M |
| Q3 2022 | 114 | $345.9M |
| Q2 2022 | 113 | $297.2M |
| Q1 2022 | 125 | $904.8M |
| Q4 2021 | 119 | $1.15B |
| Q3 2021 | 113 | $1.54B |
| Q2 2021 | 107 | $1.21B |
| Q1 2021 | 83 | $926.8M |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding C4 Therapeutics, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Two Sigma Investments, LP | 828,490 | $4.72M | 0.01% | −479,243−36.6% | Reduced |
| Two Sigma Advisers, LP | 1,065,500 | $6.07M | 0.01% | −326,400−23.4% | Reduced |
| Bain Capital Life Sciences Investors, LLC | 1,111,910 | $6.34M | 0.66% | 00.0% | Unchanged |
| Silverarc Capital Management, LLC | 1,147,891 | $6.54M | 1.47% | −294,950−20.4% | Reduced |
| Point72 Asset Management, L.P. | 1,201,848 | $6.85M | 0.02% | +923,268+331.4% | Added |
| ArrowMark Colorado Holdings LLC | 1,319,484 | $7.52M | 0.10% | +75,126+6.0% | Added |
| Geode Capital Management, LLC | 1,369,676 | $7.81M | 0.00% | +7,460+0.5% | Added |
| Bank of America Corp | 2,036,233 | $11.6M | 0.00% | +267,734+15.1% | Added |
| Morgan Stanley | 2,326,134 | $13.3M | 0.00% | +1,188,196+104.4% | Added |
| State Street Corp | 2,806,913 | $16.0M | 0.00% | −188,035−6.3% | Reduced |
| Vanguard Group Inc | 3,370,681 | $19.2M | 0.00% | −186,018−5.2% | Reduced |
| Commodore Capital LP | 3,410,384 | $19.4M | 1.21% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 4,377,900 | $25.0M | 0.46% | +2,864,842+189.3% | Added |
| Ra Capital Management, L.P. | 4,878,000 | $27.8M | 0.32% | 00.0% | Unchanged |
| BlackRock, Inc. | 4,890,935 | $27.9M | 0.00% | +4,890,935 | New |
| Wasatch Advisors Inc | 5,677,368 | $32.4M | 0.16% | +830,218+17.1% | Added |
| Soleus Capital Management, L.P. | 6,603,996 | $37.6M | 3.13% | +2,552,000+63.0% | Added |
| Lynx1 Capital Management LP | 6,880,527 | $39.2M | 13.90% | 00.0% | Unchanged |
| TCG Crossover Management, LLC | 0 | $0 | 0.00% | −1,276,574−100.0% | Sold out |
| Schroder Investment Management Group | 0 | $0 | 0.00% | −405,885−100.0% | Sold out |
| Atom Investors LP | 0 | $0 | 0.00% | −332,620−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −258,426−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −235,200−100.0% | Sold out |
| Capital Fund Management S.A. | 0 | $0 | 0.00% | −220,517−100.0% | Sold out |
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −113,436−100.0% | Sold out |
| Bellevue Group AG | 0 | $0 | 0.00% | −57,600−100.0% | Sold out |
| Alpine Global Management, LLC | 0 | $0 | 0.00% | −57,528−100.0% | Sold out |
| Bridgeway Capital Management, LLC | 0 | $0 | 0.00% | −49,000−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −39,976−100.0% | Sold out |
| Brevan Howard Capital Management LP | 0 | $0 | 0.00% | −33,511−100.0% | Sold out |
| Corton Capital Inc. | 0 | $0 | 0.00% | −31,959−100.0% | Sold out |
| Catalyst Funds Management Pty Ltd | 0 | $0 | 0.00% | −23,228−100.0% | Sold out |
| Aquatic Capital Management LLC | 0 | $0 | 0.00% | −20,700−100.0% | Sold out |
| Fox Run Management, L.L.C. | 0 | $0 | 0.00% | −14,973−100.0% | Sold out |
| Marathon Trading Investment Management LLC | 0 | $0 | 0.00% | −14,400−100.0% | Sold out |
| E Fund Management Co., Ltd. | 0 | $0 | 0.00% | −11,280−100.0% | Sold out |
| Tudor Investment Corp Et Al | 0 | $0 | 0.00% | −10,162−100.0% | Sold out |
| Headlands Technologies LLC | 0 | $0 | 0.00% | −9,652−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −1,735−100.0% | Sold out |
| Pacer Advisors, Inc. | 0 | $0 | 0.00% | −1,056−100.0% | Sold out |
| Piscataqua Savings Bank | 0 | $0 | 0.00% | −600−100.0% | Sold out |
| EntryPoint Capital, LLC | 0 | $0 | 0.00% | −458−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −316−100.0% | Sold out |
| Gradient Investments LLC | 0 | $0 | 0.00% | −25−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |
| Susquehanna Fundamental Investments, LLC | – | – | – | – | Not filed |